The Trump administration is on the brink of extending a temporary rule that allows health providers to prescribe certain controlled substances via telemedicine. This rule, enacted by the Drug Enforcement Administration during the height of the Covid-19 pandemic in March 2020, permits providers to initiate prescriptions for medications like Ritalin, Adderall for ADHD, and buprenorphine for opioid use disorder without an in-person examination.
This forthcoming extension would mark the fourth time that the federal government has prolonged these flexibilities without solidifying a permanent decision on how telemedicine prescribing of controlled substances will be regulated. The White House budget website recently posted about the “Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications,” signaling that the regulatory uncertainties will persist for at least another year.
In the past five years, the temporary telehealth flexibilities have led to the rise of businesses focused on remote prescribing of controlled substances. Critics have raised concerns about the potential for misuse or addiction when stimulants for ADHD or buprenorphine for opioid use disorder are prescribed without an in-person evaluation. However, research has shown that patients receiving ADHD medications via telehealth do not experience higher rates of addiction or adverse effects compared to those seen in a traditional doctor’s office.
The Biden administration’s delay in finalizing a telehealth rule has resulted in multiple extensions of the temporary flexibilities, now even under the Trump administration. The ongoing debate revolves around how stimulants used for ADHD treatment should be regulated and whether distinctions should be made between Schedule II and III substances.
Terry Cole, the new head of the DEA, has been noncommittal about the future of telehealth services for substance use disorders. Amidst this regulatory uncertainty, telehealth visits under Medicare have suffered a decline during the recent government shutdown, underscoring the importance of establishing clear guidelines for telemedicine practices.
In conclusion, the ongoing regulatory limbo surrounding telemedicine prescribing of controlled substances highlights the need for a comprehensive and definitive framework to govern these practices. As the debate continues, it remains to be seen how the Trump administration will navigate these complex issues in the coming months.
